Trailing Twelve Months Fully Diluted EPS of $0.34 for the twelve months ended September 30, 2017 was 26% higher as compared to $0.27 for the twelve months ended September 30, 2016

As at September 30, 2017, the Company had cash, cash equivalents, and short term investments totalling $16,509,281 as compared to $13,739,286 as at December 31, 2016 – a 20% increase

At September 30, 2017, the Company remained free of debt and had available total credit facilities of $2,560,000 including an unutilized revolving demand credit facility of $1,500,000

Total Shareholders’ Equity increased by 24% from $16,726,716 at December 31, 2016 to $20,739,115 at September 30, 2017

Trailing Twelve Months Return on Equity for the twelve months ended September 30, 2017 was 27%

“Our pharmaceutical business showed continued momentum in Q3 2017, with sales growing by 15% over Q3 2016,” commented René Goehrum, President and CEO of BioSyent. “With continued organic growth in our Canadian business from our existing product portfolio and growing demand in our International markets, we expect the momentum in our pharmaceutical business to continue.”

The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management’s Discussion and Analysis for the three and nine months ended September 30, 2017 and 2016 will be posted on www.sedar.com on November 15, 2017.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,491,295 shares issued and outstanding.

EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.